Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,742 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06380309RecruitingEarly Phase 1
Study of experimental drug IDOV-SAFE for advanced digestive cancers
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
BeijingAges 18–75 - NCT06364488Recruiting
App for monitoring depression and anxiety in pregnancy
This trial tests a mobile app called TrueBlue to help monitor depression and anxiety in new and expecting mothers. If you are pregnant or recently gave birth, the study will see if the app can make tracking your moods easier and connect you with care.
Nottingham, NottinghamshireAges 18 years+ - NCT06355791Recruiting
Study of the Minuteman device for spine fusion
This study looks at how well the Minuteman device works for people with chronic low back pain and leg symptoms caused by aging spine conditions. It tests if the device helps patients move better after surgery.
Newnan, GeorgiaAges 18 years+ - NCT06348797RecruitingPhase 1
CAR-T Cells Targeting PD-L1 and DLL3 for Small Cell Lung Cancer
This trial tests a new CAR-T cell therapy that targets two proteins (PD-L1 and DLL3) on small cell lung cancer cells. It's for people whose cancer came back or got worse after standard chemotherapy, and it aims to see if the treatment is safe and works.
Chengdu, SichuanAges 18–70 - NCT06332807RecruitingPhase 1/Phase 2
Gene therapy trial for classic PKU
This trial tests a one-time gene therapy called NGGT002 for adults with classic PKU who cannot take or do not respond well to current treatments. The goal is to see if it can safely lower blood phenylalanine levels.
Orange, CaliforniaAges 18–55 - NCT06318533RecruitingEarly Phase 1
Engineered immune cell therapy for autoimmune diseases
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
Zhenjiang, JiangsuAges 18–70 - NCT06295471Recruiting
Comparing pain and healing after two laser treatments on thighs
This study compares two types of lasers (a new DFG laser and a standard CO2 laser) to see which one causes less pain and helps your skin heal better after a fractional laser treatment on your thighs. If you're looking to improve skin texture or reduce signs of aging, this might be an option.
Boston, MassachusettsAges 18 years+ - NCT06265545Recruiting
Study for relapsed or hard-to-treat AML
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
TianjinAges Any age - NCT06267183RecruitingEarly Phase 1
Safety study of a new drug in healthy volunteers
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
ShanghaiAges 18–45 - NCT06248411RecruitingPhase 1
Study of KK2260 for advanced solid tumors
This study tests a new experimental drug, KK2260, for people with advanced or advanced solid tumors, especially esophageal cancer and certain head and neck cancers. The goal is to see if the drug is safe and helps shrink or control the cancer.
Nagoya, Aichi-kenAges 18 years+ - NCT06238401RecruitingPhase 1
Testing ACR246 for advanced solid tumors
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06210490RecruitingPhase 2
Antibody-drug combo with radiation for HER2+ UTUC after surgery
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06214156RecruitingPhase 1/Phase 2
T3011 for advanced melanoma
This trial tests a new treatment, T3011, which is a virus that targets and kills cancer cells while also boosting your immune system. It's for people with advanced melanoma, and the goal is to see if it can shrink tumors and help you live longer.
BeijingAges 18 years+ - NCT06214143RecruitingPhase 1/Phase 2
T3011 plus immunotherapy for advanced solid tumors
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
AnyangAges 18 years+ - NCT06215846Enrolling by invitationPhase 1
Study of BioTTT001 for advanced solid tumors
This trial tests a new drug, BioTTT001, given as a shot directly into tumors. It is for people with certain advanced solid tumors that have stopped responding to standard treatments or who have no other options.
Shenyang, LiaoningAges 18–80 - NCT06190275Recruiting
Immune cell therapy for advanced head and neck cancer
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+ - NCT06167694RecruitingPhase 1/Phase 2
Study of HRS-8080 and Dalpiciclib for advanced breast cancer
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
Beijing, Beijing MunicipalityAges 18–75 - NCT06162975Recruiting
Monitoring study for a tick-borne illness
This study is tracking patients with a suspected or confirmed rickettsiosis infection, which is a bacterial disease spread by ticks. It aims to see how the illness progresses and how it is treated.
Chemal, Altai RepublicAges Any age - NCT06160557Enrolling by invitation
Radiation after endoscopic surgery for superficial esophageal cancer
This trial tests if adding radiation therapy after endoscopic surgery (ESD) helps people with early-stage esophageal cancer that had certain high-risk features, like deeper invasion or positive margins. It aims to improve outcomes for those who didn't get a complete cure with surgery alone.
Fuzhou, FujianAges 18–75 - NCT04370587RecruitingPhase 1/Phase 2
Injecting a cancer medicine into tumors plus pembrolizumab
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
Gilbert, ArizonaAges 18 years+ - NCT06144671RecruitingPhase 1/Phase 2
Custom immune cell therapy for advanced solid tumors
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06146231Recruiting
Breast reconstruction with Motiva implants and fat grafting
This study tests a new breast reconstruction method using Motiva Flora implants and your own fat to rebuild the breast after a mastectomy. It is for women who need tissue expansion as part of their reconstruction and have completed cancer treatments at least one year earlier.
GhentAges 18 years+
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,742 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.